At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients With Primary Aldosteronism
In Brief
A Phase 2 clinical trial evaluating CIN-107 2 mg dosing, CIN-107 4 mg dosing, and 1 other intervention for Primary Aldosteronism and Hyperaldosteronism. Completed, enrolled 15 participants across 10 sites.
Detailed Summary
This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part 2 for up to 74 weeks for evidence of long-term safety and tolerability.
Study Details
Timeline
Interventions
One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.